Marshall Wace, LLP Protalix Bio Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 615,085 shares of PLX stock, worth $959,532. This represents 0.0% of its overall portfolio holdings.
Number of Shares
615,085
Previous 101,899
503.62%
Holding current value
$959,532
Previous $195,000
707.18%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
8.27MCall Options Held
227KPut Options Held
54.5K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.19MShares$1.85 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny963KShares$1.5 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA859KShares$1.34 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL685KShares$1.07 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.483KShares$753,2850.01% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $77.6M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...